What is Mosquirix, the world’s first malaria vaccine to get WHO’s approval?


Mosquirix (RTS,S), recommended by WHO for widespread use, is the first vaccine that is around 30% effective against severe cases of the mosquito-borne disease malaria and is given to children aged 6 weeks to 17 months. GlaxoSmithKline’s four-dose vaccine, which was under development for 30 years, acts against Plasmodium falciparum, the deadliest malaria parasite, which is most prevalent in Africa.

IJSRD CALL FOR PAPER – VOLUME 8 | ISSUE 11 – JANUARY 2021


IJSRD – International Journal for Scientific Research and Development is a leading Online Open-Access peer reviewed journal. E-journal publishes original and quality Research papers. ISSN International (NISCAIR) approved ISSN. 

CALL FOR PAPER – Volume 8 | Issue 11 – January 2021

Global Indexing of your published papers. 
Submit your Research Paper Online @ijsrd.com 
IMPACT FACTOR: 4.396 (SJIF) | IC Value: 66.68 
✉ Info@ijsrd.com | ✆ 08866191212/22

IJSRD Submit Paper | Vol 7 Iss. 9 – Nov’ 19


IJSRD – International Journal for Scientific Research & Development

Call for Papers – Nov. 2019 | Vol. 7 Issue 9

IF : 4.396 | I.C.Value : 66.68

For More Information or Query ✆ 08866191212/22

Email us:

Submit Paper on http://www.ijsrd.com

IJSRD_NOVEMBER_2019 (1)